Newsfeeds - Spark Newswire

1 minute read

Morgan Stanley Initiates Coverage On Lyell Immunopharma with Overweight Rating, Announces Price Target of $25

Today, 6:33 PM

Morgan Stanley analyst Matthew Harrison initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Overweight rating and announces Price Target of $25.

LYEL

1 minute read

B of A Securities Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $25

By Benzinga Newsdesk

Today, 6:33 PM

B of A Securities analyst Geoff Meacham initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Buy rating and announces Price Target of $25.

LYEL

1 minute read

JP Morgan Initiates Coverage On Lyell Immunopharma with Overweight Rating, Announces Price Target of $22

By Benzinga Newsdesk

Today, 6:33 PM

JP Morgan initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Overweight rating and announces Price Target of $22.

LYEL

1 minute read

Goldman Sachs Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $30

By Benzinga Newsdesk

Today, 6:33 PM

Goldman Sachs analyst Salveen Richter initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Buy rating and announces Price Target of $30.

LYEL

3 minute read

The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix

By Shanthi Rexaline

Today, 6:33 PM

Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow.

ALEC

5 minute read

The Daily Biotech Pulse: Lilly, Morphic’s Positive Data At ECCO, Humanigen’s COVID Treatment Gets Expedited Review In UK, TransCode IPO

By Shanthi Rexaline

Today, 6:33 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)

ABCL

3 minute read

IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings

By Chris Katje

Today, 6:33 PM

This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.

ABBV